Search Results for “EC” – Page 248 – media

NIHR and TJBCM announce new funding initiative for novel brain tumour research

The condition is the ninth most common cancer in the UK and affects 12,300 people annually The National Institute for Health and Care Research (NIHR) and the Tessa Jowell Brain Cancer Mission (TJBCM) have announced a new innovative package of research funding to stimulate brain tumour research in adults, children and young people. The announcement emerges from a collaboration between charities, research funders and the government, which pledged £40m to develop new lifesaving and life-improving research. Currently the ninth most common cancer in the UK, affecting around 12,300 people every year, according to the Brain Tumour Charity, brain tumours occur when a growth of cells in the brain multiplies in an abnormal, uncontrollable way. In 2018, members of the brain tumour community united to design a national strategy and the government committed funding for new research, following the late Dame Tessa Jowell’s call to action on behalf of brain tumour ...
- Source: drugdu
- 89
- May 17, 2024
First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab

Shanghai, China, May 15, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient has been dosed in the phase 3 stage of the international multi-centre clinical trial (ASTRUM-015) of the company’s self-developed anti-PD-1 mAb HANSIZHUANG (serplulimab) in combination with bevacizumab and chemotherapy in patients with metastatic colorectal cancer (mCRC). The leading principal investigator is Professor Rui-Hua Xu from Sun Yat-sen University Cancer Center and State Key Laboratory of Oncology in South China. Currently, for mCRC patients, immunotherapies have been proven to bring hope to patients with mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) but have not yet shown meaningful positive outcomes in those with proficient mismatch repair (pMMR)/ microsatellite stable (MSS), and there is no immunotherapy approved globally for the first-line treatment of mCRC. HANSIZHUANG is expected to become the world’s first anti-PD-1 mAb for the first-line treatment of mCRC. Colorectal cancer (CRC) is one of the most ...
- Source: drugdu
- 73
- May 17, 2024
Companies prepare for ADC trial readouts at ASCO 2024

As the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting approaches at the end of this month, Merck & Co joined a host of other companies that have announced upcoming data presentations for their oncology clinical studies at the event. The ASCO annual meeting, taking place from 31 May to 4 June, gathers pharmaceutical companies, healthcare providers and experts, to discuss the latest trends in oncology and share new data from ongoing and completed clinical studies. In the last few days, several companies such as Merck & Co, Astellas, and Pfizer have announced upcoming data presentations to look for at the premier cancer conference. In a 15 May press release, Merck & Co announced that it would present data from its Phase III study (NCT06312176), investigating the antibody-drug conjugate therapy (ADC), Sac-TMT (sacituzumab tirumotecan), in previously treated locally recurrent or metastatic triple-negative breast cancer. Pfizer will also be presenting ...
- Source: drugdu
- 112
- May 17, 2024
Medical Fair China 2024

Organiser:Messe Düsseldorf Time:21- 23 August 2024 address：No. 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou City Exhibition hall: Suzhou International Expo Centre, China Product range: Hospital facilities and equipment: Medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical examination and analysis instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, disposable medical supplies, dressings and hygiene materials, all kinds of surgical instruments Hospital wards, operating rooms, emergency room equipment, hospital office equipment, laboratory equipment, beds, operating tables, operating table spotlights, inspection Check the bed, gums and all kinds of hospital furniture Medical care equipment: all kinds of medical and home rehabilitation physiotherapy products About CDMEE： Jiangsu Suzhou Medical Device Innovation Exhibition (Medical Fair China) with the theme of “smart health”, directly and comprehensively serving the medical device industry from the source to the terminal of the entire medical industry chain. Gather advanced medical technology products at ...
- Source: drugdu
- 144
- May 17, 2024
New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several hundred thousand hospitalizations and as many as 51,000 deaths. Syndromic testing systems have improved the detection of co-infections, thus reducing the need for further testing. These systems provide rapid results, enabling healthcare providers to make timely decisions and stop unnecessary antibiotic treatments when viral pathogens are identified, which helps reduce antibiotic use and supports responsible antimicrobial stewardship. A new respiratory syndromic testing panel now allows for the accurate diagnosis of respiratory infections and the detection of co-infections. This panel delivers results in about one hour and requires less than one minute of hands-on time, while providing easy access to cycle threshold (Ct) values and amplification curves. QIAGEN N.V. (Venlo, the Netherlands) has received clearance from the U.S. Food and Drug ...
- Source: drugdu
- 88
- May 16, 2024
Results from FRONTIER 2 Trial Show Promise of Mim8 as a Potential Treatment for Hemophilia A

Don Tracy, Associate Editor In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes. Novo Nordisk announced successful results from the Phase IIIa FRONTIER 2 trial, which evaluated the efficacy and safety of Mim8, a promising new treatment for hemophilia A. According to the company, this trial enrolled 254 participants over the age of 12 years to analyze the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment. The trial met its two primary endpoints, which were to demonstrate significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly administration of Mim8.1 “We are very pleased with the positive results from the FRONTIER 2 clinical trial. These data demonstrate the ability of Mim8 to prevent bleeding episodes effectively and safely in people with ...
- Source: drugdu
- 99
- May 16, 2024
AbbVie, Gilgamesh Pharmaceuticals Agree to Terms on a Collaboration to Develop Advanced Therapies for Psychiatric Disorders

The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.AbbVie and Gilgamesh Pharmaceuticals have announced a partnership focused on the development of therapies for psychiatric disorders. The collaboration seeks to leverage AbbVie’s experience in psychiatry and Gilgamesh’s research platform that focuses on neuroplastogens, which works to treat psychiatric conditions while minimizing adverse effects attributed to psychedelic compounds. According to the companies, the overall goal is to provide new opportunities in areas that haven’t provided manysolutions for patients with mood and anxiety disorders through the use of neuroplastogens. Under terms of the deal, AbbVie is expected to focus on future development and commercialization activities, while Gilgamesh will receive $65 million as an upfront payment. Upon the completion of specific milestones, including option fees and tiered royalties on net sales, Gilgamesh could potentially receive up to $1.95 billion.1 “Significant unmet need remains for ...
- Source: drugdu
- 102
- May 16, 2024
BBSRC invests £48m in Babraham Institute to advance lifelong health research

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability to protect health and counter age-related decline, including cellular response to stress, epigenetic control across the life course, immunity, resilience and repair. In close collaboration with partners across academia, including the BBSRC’s other strategically supported research institutes and companies based on the Babraham Research Campus, the research will be delivered ...
- Source: drugdu
- 100
- May 16, 2024
【EXPERT Q&A】What does the 4-digit number next to the CE mark on medical devices mean?

Drugdu.com expert’s response: The 4-digit number next to the CE mark on medical devices indicates the Notified Body identification number (or Module D number). These digits identify the Notified Body that has certified the device’s quality management system. It signifies the registration number of the certifying body, indicating that it has assessed the quality management system of the medical device and confirmed its compliance with the relevant European Union directive requirements. This number is crucial for tracking the validity of the certification and for regulatory purposes.
- Source: drugdu
- 131
- May 16, 2024
FDA Grants Priority Review Biologics License Application to Dupixent Add-On Maintenance for the Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

Don Tracy, Associate Editor Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled. Regeneron and Sanofi announced that the FDA has granted Priority Review to their supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years who have chronic rhinosinusitis with nasal polyposis (CRSwNP) and whose condition is inadequately controlled. With the treatment already approved for adults with CRSwNP, the FDA is expected to make a final decision on the sBLA for the expanded indication by September 15, 2024.1 According to the companies, the application is supported by efficacy data from SINUS-24 and SINUS-52, two trials that showed major improvements in nasal congestion/obstruction severity, nasal polyp size, sense of smell, and a reduction in the need for systemic corticosteroids or surgery. In 2019, Regeneron first released the results of both trials, ...
- Source: drugdu
- 78
- May 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.